These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6354509)

  • 21. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer.
    Falkson G; Tormey DC; Carey P; Witte R; Falkson HC
    Eur J Cancer; 1991; 27(8):973-7. PubMed ID: 1832906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
    Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
    J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chemotherapy of breast cancers. Coordinated evolution of therapeutic schemes from 1975 to 1985].
    Chauvergne J; Durand M; Mauriac L; Hoerni B; David M
    Rev Fr Gynecol Obstet; 1986 Mar; 81(3):119-22. PubMed ID: 3085195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
    J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen.
    Mouridsen HT; Rose C; Engelsman E; Sylvester R; Rotmensz N
    Eur J Cancer Clin Oncol; 1985 Mar; 21(3):291-9. PubMed ID: 3891357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone.
    Parvinen LM; Numminen S
    Acta Radiol Oncol; 1985; 24(5):391-4. PubMed ID: 3002135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report.
    Oster MW; Park Y
    Cancer; 1983 Jan; 51(2):203-5. PubMed ID: 6821812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
    Moliterni A; Bonadonna G; Valagussa P; Ferrari L; Zambetti M
    J Clin Oncol; 1991 Jul; 9(7):1124-30. PubMed ID: 2045854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
    Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
    J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
    Cocconi G; Bisagni G; Bacchi M; Buzzi F; Canaletti R; Carpi A; Ceci G; Colozza A; De Lisi V; Lottici R
    Ann Oncol; 1990; 1(1):36-44. PubMed ID: 2078484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer].
    Yasutake K; Imamura Y; Yoshimura Y; Oya M; Matsushita K; Hozumi T; Katou J; Okutani T; Irie K
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2373-9. PubMed ID: 2502072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
    De Lena M; Brambilla C; Morabito A; Bonadonna G
    Cancer; 1975 Apr; 35(4):1108-15. PubMed ID: 1116104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy.
    Morris DM; Elias EG; Didolkar MS; Brown SD
    J Surg Oncol; 1985 Jul; 29(3):154-7. PubMed ID: 3001423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
    Neoplasma; 1985; 32(3):381-7. PubMed ID: 2862594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.
    Viladiu P; Alonso MC; Avella A; Beltrán M; Borrás J; Ojeda B; Bosch FX
    Cancer; 1985 Dec; 56(12):2745-50. PubMed ID: 3902200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.
    Powles TJ; Jones AL; Judson IR; Hardy JR; Ashley SE
    Br J Cancer; 1991 Aug; 64(2):406-10. PubMed ID: 1892775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer.
    Steiner R; Stewart JF; Cantwell BM; Minton MJ; Knight RK; Rubens RD
    Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1553-7. PubMed ID: 6357805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.